LYEL — Lyell Immunopharma, Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2021-06-17.
Performance
Technicals
Others in Healthcare
Measured signals that fired on LYEL
| date | signal | measured base rate |
|---|---|---|
| 2026-03-23 | Equal lows taken out structure | -0.64% over 21 days · t = -4.75 · n = 55,661 statistically distinguishable from its control group |
| 2026-03-09 | Cluster buy: three or more insiders insider | +0.63% over 21 days · t = 1.84 · n = 3,050 not distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-08-10 | Bulis Veronica Sanchez VP, Corporate Controller | Open-market sale | 621 | 14.34 | 8.9K |
| 2026-08-10 | Seely Lynn President and CEO | Open-market sale | 390 | 14.34 | 5.6K |
| 2026-08-10 | Lee Gary K. Chief Scientific Officer | Open-market sale | 131 | 14.34 | 1.9K |
| 2026-08-10 | Hill Stephen J. Chief Operating Officer | Open-market sale | 89 | 14.34 | 1.3K |
| 2026-07-27 | Innovative Cellular Therapeutics Holdings Ltd 10% owner | Other Acquisition/Disposition | 38.5K | 0.00 | 0 |
| 2026-07-27 | Innovative Cellular Therapeutics Holdings Ltd 10% owner | Other Acquisition/Disposition | 44.0K | 0.00 | 0 |
| 2026-07-17 | Innovative Cellular Therapeutics Holdings Ltd 10% owner | Open-market sale 10b5-1 plan | 10 | 13.70 | 137 |
| 2026-07-16 | Innovative Cellular Therapeutics Holdings Ltd 10% owner | Open-market sale 10b5-1 plan | 10 | 13.73 | 137 |
| 2026-06-29 | Innovative Cellular Therapeutics Holdings Ltd 10% owner | Other Acquisition/Disposition | 76.0K | 0.00 | 0 |
| 2026-06-15 | Innovative Cellular Therapeutics Holdings Ltd 10% owner | Other Acquisition/Disposition | 66.5K | 0.00 | 0 |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| ARCH Venture Management, LLC | 65.1M | 3.2M |
| GSK plc | 30.3M | 1.5M |
| Foresite Capital Management IV, LLC | 16.1M | 800.4K |
| Orland Properties Ltd | 15.1M | 754.7K |
| VANGUARD CAPITAL MANAGEMENT LLC | 14.4M | 718.2K |
| Almitas Capital LLC | 11.6M | 577.8K |
| Foresite Capital Management V, LLC | 9.6M | 477.1K |
| MILLENNIUM MANAGEMENT LLC | 9.2M | 458.9K |
| CITADEL ADVISORS LLC | 7.7M | 381.5K |
| venBio Partners LLC | 6.8M | 337.7K |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Latest SEC filings
| form | filed | period | |
|---|---|---|---|
| SCHEDULE 13G/A | 2026-08-14 | — | on EDGAR ↗ |
| 4 | 2026-08-11 | 2026-08-10 | on EDGAR ↗ |
| 4 | 2026-08-11 | 2026-08-10 | on EDGAR ↗ |
| 4 | 2026-08-11 | 2026-08-10 | on EDGAR ↗ |
| 4 | 2026-08-11 | 2026-08-10 | on EDGAR ↗ |
| 10-Q | 2026-08-06 | 2026-06-30 | on EDGAR ↗ |
| 8-K | 2026-08-06 | 2026-08-06 | on EDGAR ↗ |
| 4 | 2026-07-27 | 2026-07-27 | on EDGAR ↗ |
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Ask the AI about LYEL
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →